These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6443767)

  • 1. Host defense mechanisms against pneumonia due to Pseudomonas aeruginosa.
    Pennington JE; Ehrie MG; Hickey WF
    Rev Infect Dis; 1984; 6 Suppl 3():S657-66. PubMed ID: 6443767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism for pulmonary protection by lipopolysaccharide pseudomonas vaccine.
    Pennington JE; Kuchmy D
    J Infect Dis; 1980 Aug; 142(2):191-8. PubMed ID: 6774032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pseudomonas aeruginosa immunoglobulin in experimental pneumonia].
    Pennington JE; Pier GB
    Infection; 1987; 15(1):56-9. PubMed ID: 3106230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of cyclophosphamide and cortisone acetate on bronchoalveolar phagocytic cell populations.
    Pennington JE
    Am Rev Respir Dis; 1978 Aug; 118(2):319-24. PubMed ID: 697182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of cell wall Pseudomonas aeruginosa vaccines for protection against experimental pneumonia.
    Pennington JE; Pier GB
    Rev Infect Dis; 1983; 5 Suppl 5():S852-7. PubMed ID: 6419311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia.
    Naito Y; Hamaoka S; Kinoshita M; Kainuma A; Shimizu M; Katoh H; Moriyama K; Ishii KJ; Sawa T
    Microbiol Immunol; 2018 Dec; 62(12):774-785. PubMed ID: 30378708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.
    Sawa T; Ito E; Nguyen VH; Haight M
    Hum Vaccin Immunother; 2014; 10(10):2843-52. PubMed ID: 25483637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipopolysaccharide pseudomonas vaccine: efficacy against pulmonary infection with Pseudomonas aeruginosa.
    Pennington JE
    J Infect Dis; 1979 Jul; 140(1):73-80. PubMed ID: 110888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage FABP4 is required for neutrophil recruitment and bacterial clearance in Pseudomonas aeruginosa pneumonia.
    Liang X; Gupta K; Quintero JR; Cernadas M; Kobzik L; Christou H; Pier GB; Owen CA; Çataltepe S
    FASEB J; 2019 Mar; 33(3):3562-3574. PubMed ID: 30462529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of lung infections caused by Pseudomonas aeruginosa in mice treated with cyclophosphamide.
    Mayer P; Walzl H
    Infection; 1983; 11(2):87-96. PubMed ID: 6408008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of Pseudomonas aeruginosa pneumonia during immunosuppression.
    Pennington JE; Ehrie MG
    J Infect Dis; 1978 Jun; 137(6):764-74. PubMed ID: 96188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active and passive immunization strategies for Pseudomonas aeruginosa pneumonia.
    Pennington JE; Pier GB; Sadoff JC; Small GJ
    Rev Infect Dis; 1986; 8 Suppl 4():S426-33. PubMed ID: 2944209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active immunization with lipopolysaccharide Pseudomonas antigen for chronic Pseudomonas bronchopneumonia in guinea pigs.
    Pennington JE; Hickey WF; Blackwood LL; Arnaut MA
    J Clin Invest; 1981 Nov; 68(5):1140-8. PubMed ID: 6795229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.
    Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB
    J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
    Moriyama K; Wiener-Kronish JP; Sawa T
    Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pseudomonas aeruginosa immunoglobulin in experimental pneumonia].
    Pennington JE; Pier GB
    Infection; 1987; 15 Suppl 2():S47-50. PubMed ID: 3112020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination against Pseudomonas aeruginosa pneumonia in immunocompromised mice.
    Scarff JM; Goldberg JB
    Clin Vaccine Immunol; 2008 Feb; 15(2):367-75. PubMed ID: 18094113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.
    Eichler I; Joris L; Hsu YP; Van Wye J; Bram R; Moss R
    J Clin Invest; 1989 Dec; 84(6):1794-804. PubMed ID: 2512330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with Bivalent Flagellin Protects Mice against Fatal
    Behrouz B; Hashemi FB; Fatemi MJ; Naghavi S; Irajian G; Halabian R; Imani Fooladi AA
    J Immunol Res; 2017; 2017():5689709. PubMed ID: 29201922
    [No Abstract]   [Full Text] [Related]  

  • 20. Killed but metabolically active Pseudomonas aeruginosa-based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infections.
    Meynet E; Laurin D; Lenormand JL; Camara B; Toussaint B; Le Gouëllec A
    Vaccine; 2018 Mar; 36(14):1893-1900. PubMed ID: 29506924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.